Currently, NPPA doesn't have market data for 350 medicines that come under price control.
ALSO READ: NPPA to cap coronary stent prices
NPPA Chairman Bhupendra Singh said DPCO also has to be amended in a way that it would help the drug price controller determine the price of coronary stents. "NPPA doesn't have a benchmark to work out the pricing mechanism for agents as done for other drugs.''
ALSO READ: NPPA caps prices of another 50 drugs
At a recent meeting with NPPA and the Department of Pharmaceuticals, foreign companies had pressed for higher prices for their "next generation" stents. The government is looking at amending the draft regulation for stents.
ALSO READ: NPPA caps prices of 70 new drugs